Advertisement
Demo

Merck, Pfizer combo treatment boosts kidney cancer survival

Feb 12, 2019 , Reuters
Drugmaker Merck & Co Inc said on Monday that the combination of its cancer immunotherapy Keytruda with Pfizer Inc's Inlyta cut the risk of death nearly in half for patients with the most common form of kidney cancer when compared with treatment with chemotherapy drug Sutent.


Read the full story...


Trending healthcare news keywords at this moment

healthcare digital patients study finds data cancer disease kids mental heart medical drug fda research flu measles higher care teen risk big launches shows tech food depression tied surgery tip state products